Jazz Pharmaceuticals (JAZZ) Overweight Rating Reaffirmed at Cantor Fitzgerald themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Cantor Fitzgerald reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a research note issued to investors on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Jazz Pharmaceuticals’ FY2023 earnings at $14.27 EPS and FY2024 earnings at $15.79 EPS. Other analysts have also issued research reports about the […]
Jazz Pharmaceuticals (JAZZ) Overweight Rating Reaffirmed at Cantor Fitzgerald kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month target […]
Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price target among brokerages […]